← All trials
NCT06358638
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 3, 2024
- Primary completion
- Sep 30, 2044
- Completion date
- Sep 30, 2054
- First posted
- Apr 10, 2024
- Last posted
- Jun 20, 2024
- Enrollment
- 12
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Georgetown UniversityLead sponsor
- University of CalgaryCollaborator
- Northwestern UniversityCollaborator
- Janssen Pharmaceutica NVCollaborator
- Ohio State UniversityCollaborator
- Yeshiva UniversityCollaborator
- Georgetown UniversityOfficial
- Doris Duke Charitable FoundationCollaborator
- University of TorontoCollaborator
- Georgetown UniversitySponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.